


Serial No. 10/632,734

Attorney Docket No. R0087D-DIV

Listing of Claims

Claims 1-32 (canceled)

Claim 33 (previously amended) A compound of Formula I



wherein:

$R^1$ , and  $R^2$  are independently in each occurrence hydrogen, halogen,  $(C_{1-6})$ -alkyl,  $-OR'$ ,  $-SR'$ ,  $-NR'R''$ ,  $-SOR'$ ,  $-SO_2R'$ ,  $-COOR'$ ,  $-OCOR'$ ,  $-OCONR'R''$ ,  $-OSO_2R'$ ,  $-OSO_2NR'R''$ ;  $-NR'SO_2R''$ ,  $-NR'COR''$ ,  $-SO_2NR'R''$ ,  $-SO_2(CH_2)_{1-3}CONR'R''$ ,  $-CONR'R''$ , cyano, haloalkyl, or nitro;

$R'$  and  $R''$  are independently in each occurrence hydrogen,  $(C_{1-6})$ -alkyl, substituted lower alkyl, aryl, heterocyclyl, heteroaryl, aryl- $(C_{1-3})$ -alkyl, heteroaryl- $(C_{1-3})$ -alkyl, heterocyclyl- $(C_{1-3})$ -alkyl, cycloalkylalkyl, cycloalkyl, or  $R'$  and  $R''$  together with the nitrogen they are attached may also form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O or  $S(O)_{0-2}$ ;

$R^3$  is independently in each occurrence  $(C_{1-6})$  alkyl,  $(C_{1-6})$  alkenyl,  $(C_{1-6})$  alkynyl, or cycloalkyl;

$R^4$  is hydrogen,  $(C_{1-6})$ -alkyl, haloalkyl, aryl- $(C_{1-6})$ -alkyl, heteroaryl- $(C_{1-6})$ -alkyl,  $-(C_{1-6})-CR'R''R'''$ ,  $-COOR'$ ,  $-SO_2R'$ ,  $-C(O)R'$ ,  $-SO_2(CH_2)_{0-3}NR'R''$ ,  $-CONR'R''$ , or  $-PO(OR')_2$ , wherein  $R'$  and  $R''$  are as defined above;

"substituted lower alkyl" means the lower alkyl having one to three substituents, selected from the group consisting of hydroxyl, alkoxy, amino, amido, carboxyl, acyl, halogen, cyano, nitro and thiol;

"heteroaryl" means the monovalent aromatic cyclic radical having one to three rings of four to eight atoms per ring, incorporating one or two heteroatoms (chosen from nitrogen, oxygen or sulfur), within the ring which can optionally be substituted with one or two substituents selected from the group consisting of hydroxy, cyano, lower alkyl, lower alkoxy, lower haloalkoxy, alkylthio, halo, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino and arylcarbonylamino;

"heterocyclyl" means the monovalent saturated cyclic radical, consisting of one or two rings, of three to eight atoms per ring, incorporating one or more ring heteroatoms (chosen from N, O or  $S(O)_{0-2}$ ), and which can optionally be substituted with one or two substituents selected from the group consisting

Serial No. 10/632,734

Attorney Docket No. R0087D-DIV

of hydroxy, oxo, cyano, lower alkyl, lower alkoxy, lower haloalkoxy, alkylthio, halo, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino and arylcarbonylamino;

"cycloalkyl" means the monovalent saturated carbocyclic radical consisting of one or two rings, of three to eight carbons per ring, which can optionally be substituted with one or two substituents, selected from the group consisting of hydroxy, cyano, lower alkyl, lower alkoxy, lower haloalkoxy, alkylthio, halo, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino and arylcarbonylamino;

p is an integer from 1 to 3 inclusive;

n is an integer from 1 to 6 inclusive; and,

individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof.

34. (previously added) The compound of Claim 33, wherein p is 2.

35. (previously added) The compound of Claim 33, wherein n is 3.

36. (previously added) The compound of Claim 34, wherein n is 3.

37. (previously added) The compound of Claim 36, wherein R<sup>4</sup> is hydrogen.

38. (previously added) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 33 in admixture with a pharmaceutically acceptable carrier.

39 - 41. (canceled)

42. (currently amended) ~~The A method of treatment of Claim 41, wherein said disease state associated with treating a smooth muscle disorders is~~ disorder of the genitourinary tract ~~and is~~ selected from the group consisting of overactive bladder, detrusor hyperactivity, urgency, frequency, reduced bladder capacity, incontinence episodes, changes in bladder capacity, micturition threshold, unstable bladder contractions, sphincteric spasticity, outlet obstruction, outlet insufficiency, pelvic hypersensitivity, idiopathic

Serial No. 10/632,734


Attorney Docket No. R0087D-DIV

conditions and detrusor instability comprising administering a therapeutically effective amount of a compound according to claim 33.


43. (currently amended) ~~The  $\Delta$  method of treatment of Claim 41, wherein said disease state associated with treating a respiratory smooth muscle disorder disorders is a comprises respiratory disorder~~ selected from the group consisting of allergies, asthma, chronic obstructive pulmonary disease and pulmonary fibrosis comprising administering a therapeutically effective amount of a compound according to claim 33.

44. (currently amended) ~~The  $\Delta$  method of treatment of Claim 41, wherein the disease state associated with treating a gastrointestinal tract disorders is smooth muscle disorder~~ selected from the group consisting of irritable bowel syndrome, diverticular disease, gastrointestinal hypermobility disorders and diarrhea comprising administering a therapeutically effective amount of a compound according to claim 33.


45. (previously amended) A process for preparing a compound as claimed in Claim 33 which process comprises reacting a compound having a formula



with a compound of formula



to provide a compound of Formula I



wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $p$  and  $n$  are as defined in Claim 33.

\* \* \* \* \*

Serial No. 10/632,734


Attorney Docket No. R0087D-DIV

conditions and detrusor instability comprising administering a therapeutically effective amount of a compound according to claim 33.


43. (currently amended) ~~The  $\Delta$  method of treatment of Claim 41, wherein said disease state associated with treating a respiratory smooth muscle disorder disorders is a comprises respiratory disorder~~ selected from the group consisting of allergies, asthma, chronic obstructive pulmonary disease and pulmonary fibrosis comprising administering a therapeutically effective amount of a compound according to claim 33.

44. (currently amended) ~~The  $\Delta$  method of treatment of Claim 41, wherein the disease state associated with treating a gastrointestinal tract smooth muscle disorders is~~ selected from the group consisting of irritable bowel syndrome, diverticular disease, gastrointestinal hypermobility disorders and diarrhea comprising administering a therapeutically effective amount of a compound according to claim 33.


45. (previously amended) A process for preparing a compound as claimed in Claim 33 which process comprises reacting a compound having a formula



with a compound of formula



to provide a compound of Formula I



wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $p$  and  $n$  are as defined in Claim 33.

\* \* \* \* \*